Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.Annals of the American Thoracic Society · 2014
   Trial
2. Bibliometric analysis of intestinal microbiota and lung diseases.Frontiers in cellular and infection microbiology · 2024
   Article
3. The Potential of Probiotics as Ingestible Adjuvants and Immune Modulators for Antiviral Immunity and Management of SARS-CoV-2 Infection and COVID-19.Pathogens (Basel, Switzerland) · 2023
   Review
4. Nasal Priming with Lactobacillus rhamnosus CRL1505 Stimulates Mononuclear Phagocytes of Immunocompromised Malnourished Mice: Improvement of Respiratory Immune Response.Probiotics and antimicrobial proteins · 2020
   Article
5. Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection.Physiological reviews · 2018
   Review
6. The Human Microbiome in the Fight Against Tuberculosis.The American journal of tropical medicine and hygiene · 2017
   Review
7. Investigation of Streptococcus salivarius-mediated inhibition of pneumococcal adherence to pharyngeal epithelial cells.BMC microbiology · 2016
   Article
8. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.Clinical drug investigation · 2016
   Article
9. Novel microbiome-based therapeutics for chronic rhinosinusitis.Current allergy and asthma reports · 2015
   Article
10. The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography.American journal of respiratory and critical care medicine · 2014
    Article
11. Investigating the effects of probiotics on pneumococcal colonization using an in vitro adherence assay.Journal of visualized experiments : JoVE · 2014
    Article
12. Secondary bacterial infections in influenza virus infection pathogenesis.Current topics in microbiology and immunology · 2014
    Review
13. Otitis media among high-risk populations: can probiotics inhibit Streptococcus pneumoniae colonisation and the risk of disease?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013
    Review
14. The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013
    Article
15. Inhibition of Streptococcus pneumoniae adherence to human epithelial cells in vitro by the probiotic Lactobacillus rhamnosus GG.BMC research notes · 2013
    Article
16. Implications of the human microbiome project for epidemiology.American journal of epidemiology · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as